Hsbc Holdings PLC Sells 2,303 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Hsbc Holdings PLC trimmed its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 11.3% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 18,086 shares of the biotechnology company’s stock after selling 2,303 shares during the quarter. Hsbc Holdings PLC owned about 0.09% of Enanta Pharmaceuticals worth $226,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ENTA. Allspring Global Investments Holdings LLC bought a new stake in shares of Enanta Pharmaceuticals in the second quarter worth approximately $35,000. State Board of Administration of Florida Retirement System purchased a new stake in Enanta Pharmaceuticals during the 1st quarter valued at $118,000. Quest Partners LLC lifted its holdings in shares of Enanta Pharmaceuticals by 511.2% during the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 9,692 shares during the period. Virtu Financial LLC bought a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at $191,000. Finally, Pennant Investors LP purchased a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth $330,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Insider Activity

In related news, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the sale, the insider now owns 23,988 shares in the company, valued at approximately $361,499.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Enanta Pharmaceuticals news, insider Scott T. Rottinghaus sold 5,375 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $17.08, for a total value of $91,805.00. Following the sale, the insider now owns 21,717 shares in the company, valued at $370,926.36. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Scott T. Rottinghaus sold 4,299 shares of the firm’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $15.07, for a total value of $64,785.93. Following the transaction, the insider now owns 23,988 shares of the company’s stock, valued at approximately $361,499.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 13.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. JMP Securities reiterated a “market outperform” rating and set a $22.00 price objective on shares of Enanta Pharmaceuticals in a research report on Friday, September 27th. Evercore ISI upgraded shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. JPMorgan Chase & Co. cut their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research report on Tuesday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Enanta Pharmaceuticals Trading Up 2.0 %

Enanta Pharmaceuticals stock opened at $11.41 on Friday. Enanta Pharmaceuticals, Inc. has a 12-month low of $8.08 and a 12-month high of $17.80. The firm has a market capitalization of $241.65 million, a price-to-earnings ratio of -1.83 and a beta of 0.58. The firm has a 50 day moving average of $12.29 and a 200 day moving average of $13.34.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The firm had revenue of $17.97 million during the quarter, compared to analysts’ expectations of $17.44 million. During the same period in the prior year, the company posted ($1.27) earnings per share. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. On average, analysts predict that Enanta Pharmaceuticals, Inc. will post -5.3 EPS for the current year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.